Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | PGK2 | P07205 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364707 | 0.89 | TDP1 (0.59) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL4428348 | 0.88 | MAOA (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL19229493 | 0.87 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL46654 | 0.82 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL30736664 | 0.81 | TDP1 (0.50) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3341020 | 0.81 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL12434722 | 0.80 | MEN1 (0.50) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL594676 | 0.80 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| Ammonia Solution, Strong SCHEMBL17160804 | 0.80 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL17038780 | 0.79 | PGK1 (0.47) | PGK1PGK2EPHX1ANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| CN-1044911-C | Process for preparing prodrug | IGEN INC (US) | 1999-09-01 | — | — | CN | disclosed |
| CN-1217335-A | Method for preparing precursor medicine | IGEN INC (US) | 1999-05-26 | — | — | CN | disclosed |
| CN-1070409-A | Prodrugs activated by targetted catalytic proteins | IGEN INC (US) | 1993-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | TDP1 841/4885MEN1 2940/4885GAA 166/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | TDP1 841/4885MEN1 2940/4885GAA 166/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | TDP1 4456/4885MEN1 284/4885GAA 1827/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | TDP1 3296/4885MEN1 823/4885GAA 3663/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | TDP1 3296/4885MEN1 823/4885GAA 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.